Showing Latest Articles
Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy
Journal of Hematology & Oncology, 08/17/2011
Clinical Article
Kim Y et al. – This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.
Methods- 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy
- From 4 Korean institutions
- 36 patients (30.5%) had low absolute lymphocyte count (ALC, <1.0 x 109/L) at diagnosis
- Patients with lymphopenia had shorter OS and PFS rates compared with patients with high ALCs (P=0.003, P=0.012, respectively)
- In multivariate analysis, high-intermediate/high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS
- Treatment-related mortality was 25.0% in low ALC group and 4.8% in high ALC group (P=0.003)
- In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P=0.002, P=0.001, respectively)
